The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Gemcitabine is a novel antimetabolite which has shown antitumor activity against a variety of tumors including non-small-cell lung cancer (NSCLC). Phase I clinical trials with gemcitabine revealed it was well tolerated and several phase II trials were conducted. This report will summarize the data from 15 phase I-II trials conducted in both untreated and treated patients with advanced lung cancer. Overall, single-agent gemcitabine was active with response rates in untreated patients ranging from 14%-33% and 0%-25% in previously treated patients. Grade 4 toxicities were infrequent with neutropenia reported in 2%-6% of patients and grade 4 thrombocytopenia was rare (1%). One randomized phase III trial comparing the efficacy and safety of gemcitabine to best supportive care confirmed the role of gemcitabine as an active agent for the treatment of NSCLC. Furthermore, gemcitabine was shown in several economic models to be cost-effective. In summary single agent gemcitabine is active, minimally toxic, and cost-effective as a treatment regimen for patients with advanced lung cancer. Studies combining gemcitabine with other active agents are underway and have reported promising results. As monotherapy, gemcitabine may make a valuable contribution to those patients with a poor performance status or comorbid diseases desiring treatment studies in this setting should also be considered.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume10
Issue numberSUPPL. 5
StatePublished - 1999
Externally publishedYes

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Therapeutics
Lung Neoplasms
Economic Models
Costs and Cost Analysis
Antimetabolites
Clinical Trials, Phase I
Poisons
Neutropenia

Keywords

  • Gemcitabine
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer. / Kelly, Karen.

In: Annals of Oncology, Vol. 10, No. SUPPL. 5, 1999.

Research output: Contribution to journalArticle

@article{9b933e007df44f5ca1d159c5781b5c42,
title = "The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer",
abstract = "Gemcitabine is a novel antimetabolite which has shown antitumor activity against a variety of tumors including non-small-cell lung cancer (NSCLC). Phase I clinical trials with gemcitabine revealed it was well tolerated and several phase II trials were conducted. This report will summarize the data from 15 phase I-II trials conducted in both untreated and treated patients with advanced lung cancer. Overall, single-agent gemcitabine was active with response rates in untreated patients ranging from 14{\%}-33{\%} and 0{\%}-25{\%} in previously treated patients. Grade 4 toxicities were infrequent with neutropenia reported in 2{\%}-6{\%} of patients and grade 4 thrombocytopenia was rare (1{\%}). One randomized phase III trial comparing the efficacy and safety of gemcitabine to best supportive care confirmed the role of gemcitabine as an active agent for the treatment of NSCLC. Furthermore, gemcitabine was shown in several economic models to be cost-effective. In summary single agent gemcitabine is active, minimally toxic, and cost-effective as a treatment regimen for patients with advanced lung cancer. Studies combining gemcitabine with other active agents are underway and have reported promising results. As monotherapy, gemcitabine may make a valuable contribution to those patients with a poor performance status or comorbid diseases desiring treatment studies in this setting should also be considered.",
keywords = "Gemcitabine, Non-small-cell lung cancer",
author = "Karen Kelly",
year = "1999",
language = "English (US)",
volume = "10",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer

AU - Kelly, Karen

PY - 1999

Y1 - 1999

N2 - Gemcitabine is a novel antimetabolite which has shown antitumor activity against a variety of tumors including non-small-cell lung cancer (NSCLC). Phase I clinical trials with gemcitabine revealed it was well tolerated and several phase II trials were conducted. This report will summarize the data from 15 phase I-II trials conducted in both untreated and treated patients with advanced lung cancer. Overall, single-agent gemcitabine was active with response rates in untreated patients ranging from 14%-33% and 0%-25% in previously treated patients. Grade 4 toxicities were infrequent with neutropenia reported in 2%-6% of patients and grade 4 thrombocytopenia was rare (1%). One randomized phase III trial comparing the efficacy and safety of gemcitabine to best supportive care confirmed the role of gemcitabine as an active agent for the treatment of NSCLC. Furthermore, gemcitabine was shown in several economic models to be cost-effective. In summary single agent gemcitabine is active, minimally toxic, and cost-effective as a treatment regimen for patients with advanced lung cancer. Studies combining gemcitabine with other active agents are underway and have reported promising results. As monotherapy, gemcitabine may make a valuable contribution to those patients with a poor performance status or comorbid diseases desiring treatment studies in this setting should also be considered.

AB - Gemcitabine is a novel antimetabolite which has shown antitumor activity against a variety of tumors including non-small-cell lung cancer (NSCLC). Phase I clinical trials with gemcitabine revealed it was well tolerated and several phase II trials were conducted. This report will summarize the data from 15 phase I-II trials conducted in both untreated and treated patients with advanced lung cancer. Overall, single-agent gemcitabine was active with response rates in untreated patients ranging from 14%-33% and 0%-25% in previously treated patients. Grade 4 toxicities were infrequent with neutropenia reported in 2%-6% of patients and grade 4 thrombocytopenia was rare (1%). One randomized phase III trial comparing the efficacy and safety of gemcitabine to best supportive care confirmed the role of gemcitabine as an active agent for the treatment of NSCLC. Furthermore, gemcitabine was shown in several economic models to be cost-effective. In summary single agent gemcitabine is active, minimally toxic, and cost-effective as a treatment regimen for patients with advanced lung cancer. Studies combining gemcitabine with other active agents are underway and have reported promising results. As monotherapy, gemcitabine may make a valuable contribution to those patients with a poor performance status or comorbid diseases desiring treatment studies in this setting should also be considered.

KW - Gemcitabine

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0032716342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032716342&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -